Monitor HRTX for reverse split announcement or other compliance measures in the next 180 days. Delisting risk is real but not imminent — the stock remains listed during the cure period. Watch for any equity raise that could further pressure the stock price.
Price Chart
Executive Summary
Heron Therapeutics received a Nasdaq deficiency notice on June 25, 2026, for failing to maintain a minimum $1.00 closing bid price for 30 consecutive trading days (May 12–June 24, 2026). The company has a 180-day cure period until December 22, 2026, and intends to explore options (including a potential reverse stock split) to regain compliance, but there is no certainty of success. With an $82M market cap and the stock trading below $1.00, the risk of eventual delisting is material, threatening Nasdaq listing and institutional ownership.
Key Facts
- Nasdaq deficiency notice received June 25, 2026 for bid price below $1.00 for 30 consecutive trading days (May 12–June 24, 2026)
- Initial 180-day cure period ends December 22, 2026 to regain compliance
- Company may qualify for an additional 180-day period but must meet other listing standards and potentially effect a reverse stock split
- No immediate impact on trading — shares continue on Nasdaq Capital Market under symbol HRTX
- Market cap is $82M; analyst consensus is 89% bullish (2 Strong Buy, 6 Buy, 1 Hold)
Financial Impact
No specific financial figures cited in filing; the deficiency relates to bid price below $1.00, not financial results
Risk Factors
- Failure to regain compliance within 180 days could lead to delisting from Nasdaq, severely reducing liquidity and institutional ownership
- A reverse stock split, while curing the bid price issue, could signal distress and lead to further selling pressure
- Any equity capital raise to fund operations could dilute existing shareholders and exacerbate the price decline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-282988 |
| Document: 0001193125-26-282988-index-headers.html | 0001193125-26-282988 |
| Document: 0001193125-26-282988-index.html | 0001193125-26-282988 |
| Document: 0001193125-26-282988.txt | 0001193125-26-282988 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $0.3350 | awaiting T+60 | — | $0.3000 (+10.45%) |
Aug 10, 2026 11w ago | Press Release | $0.3350 | awaiting T+60 | — | $0.3000 (+10.45%) |
Jun 25, 2026 17w ago | 8-K | $0.4300 $0.2700 | ▲ +37.21% | ▲ +43.31% | $0.3000 (+30.23%) |
Jun 2, 2026 20w ago | 8-K | $0.4500 $0.3321 | ▲ +26.20% | ▲ +28.70% | $0.3000 (+33.33%) |
May 11, 2026 24w ago | 8-K | $0.9600 $0.5048 | ▲ +47.42% | ▲ +51.81% | $0.3000 (+68.75%) |
May 11, 2026 24w ago | Press Release | $0.9600 $0.5048 | ▲ +47.42% | ▲ +51.81% | $0.3000 (+68.75%) |
Apr 30, 2026 25w ago | DEFA14A | $1.20 $0.4592 | ▼ −61.73% | ▼ −64.84% | $0.3000 (−75.00%) |
Apr 27, 2026 26w ago | Press Release | $1.21 $0.4590 | ▼ −62.07% | ▼ −66.06% | $0.3000 (−75.21%) |
Apr 6, 2026 29w ago | 8-K | $0.8100 $0.4244 | ▼ −47.60% | ▼ −61.07% | $0.3000 (−62.96%) |
Feb 26, 2026 34w ago | 8-K | $1.20 $0.8700 | ▼ −27.50% | ▼ −35.25% | $0.3000 (−75.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers